Attached files
file | filename |
---|---|
EX-99.1 - Sonoma Pharmaceuticals, Inc. | v209944_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________
FORM
8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 3, 2011
OCULUS
INNOVATIVE SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-33216
|
68-0423298
|
(State
or Other Jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
1129
N. McDowell Blvd, Petaluma, CA 94954
(Address
of principal executive offices)(Zip Code)
(707)
782-0792
(Registrants
telephone number, including area code)
N/A
(Former
name of former address if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results
of Operations and Financial Condition.
On
February 3, 2011, Oculus Innovative Sciences, Inc. issued a press release
announcing financial results for its fiscal quarter ended December 31,
2010. The full text of the press release is furnished as Exhibit
99.1.
Item
9.01 Financial
Statements and Exhibits
Exhibits
99.1 Press
Release issued by Oculus Innovative Sciences, Inc. dated February 3,
2011.
Except
for historical information herein, matters set forth in this report are
forward-looking within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995, including statements about the
Company’s commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of words
such as "commences,” “continue,” “expects,” “believes,”
and “intends,” among others. Forward-looking statements in this press
release are subject to certain risks and uncertainties inherent in the Company's
business that could cause actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical results
may not be replicated in actual patient settings, protection offered
by the Company's patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available market
for the Company's products will not be as large as
expected, the Company's products will not be able to penetrate one or
more targeted markets, revenues will not be sufficient to fund further
development and clinical studies, the Company may not meet its future
capital needs, and its ability to obtain additional funding, as well as
uncertainties relative to varying product formulations and a multitude of
diverse regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission including the annual report
on Form 10-K for the year ended March 31, 2010. Oculus Innovative Sciences
disclaims any obligation to update these forward-looking statements except as
required by law.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: February
3, 2011
|
/s/ Robert
Miller
|
|
(Signature)
|
||
Name:
|
Robert
Miller
|
|
Title:
|
Chief
Financial
Officer
|